PMID- 35023807
OWN - NLM
STAT- MEDLINE
DCOM- 20220207
LR  - 20220430
IS  - 1941-837X (Electronic)
IS  - 1369-6998 (Linking)
VI  - 25
IP  - 1
DP  - 2022 Jan-Dec
TI  - Incidence of corneal adverse events in patients with multiple myeloma and their 
      clinical and economic impact: A real-world retrospective cohort study.
PG  - 182-192
LID - 10.1080/13696998.2022.2029088 [doi]
AB  - AIMS: Ocular toxicities are common adverse events (AEs) associated with 
      anticancer agents. There is a paucity of data documenting their impact on patient 
      care. This study assessed the clinical and economic burden of corneal AEs and 
      related symptoms (collectively termed corneal AEs) in patients receiving multiple 
      myeloma (MM) treatment. MATERIALS AND METHODS: Adults with a newly diagnosed MM 
      (MM cohort) were identified from PharMetrics Plus, a US insurance claims 
      database. Incidence, outpatient (OP) care, emergency department (ED) visits, 
      hospitalizations, and costs were assessed for corneal AEs of interest: 
      keratopathy/keratitis, blurred vision/decreased acuity, dry eye, eye pain, and 
      photophobia. Incidence of new corneal AEs, healthcare resource utilization 
      (HCRU), corneal AE-related HCRU, and costs were assessed and benchmarked against 
      a hematology cohort of patients. RESULTS: The MM cohort included 2,120 patients 
      with a median follow-up of 734.5 days. Overall, 11.7% of patients in the MM 
      cohort and 7.4% in the hematology cohort had >/=1 corneal AE of interest. In the MM 
      cohort, dry eye (6.1%), blurred vision/decreased acuity (3.4%), and 
      keratopathy/keratitis (2.5%) were the most frequent. The overall median corneal 
      AE-related per-patient-per-month (PPPM) cost was $27, predominantly contributed 
      by OP care (median $19 PPPM). During follow-up, 4.8% of patients visited the ED, 
      3.6% were hospitalized, and 42.5% of patients visited an 
      ophthalmologist/optometrist ( approximately 1.69 visits/year). Costs of these visits were 
      negligible (median PPPM $19) compared to total all-cause costs (median PPPM 
      $17,286). LIMITATIONS: The results can only be generalized to commercially 
      insured and Medicare Advantage patients. Claims-based diagnosis of corneal AEs 
      may underestimate true incidences. CONCLUSIONS: Corneal AEs were observed in  approximately 12% 
      of patients in the MM cohort, the most common were keratopathy/keratitis, dry 
      eye, and blurred vision. Most of them required only OP care. The clinical and 
      economic burden for treating corneal AEs was low when compared with total 
      all-cause or MM-related PPPM costs.
FAU - Wang, Feng
AU  - Wang F
AD  - GlaxoSmithKline, Philadelphia, PA, USA.
FAU - Sansbury, Leah
AU  - Sansbury L
AD  - GlaxoSmithKline, Research Triangle Park, NC, USA.
FAU - Ferrante, Shannon
AU  - Ferrante S
AD  - GlaxoSmithKline, Philadelphia, PA, USA.
FAU - Maiese, Eric M
AU  - Maiese EM
AD  - GlaxoSmithKline, Philadelphia, PA, USA.
FAU - Willson, Jenny
AU  - Willson J
AD  - GlaxoSmithKline, London, UK.
FAU - Chen, Chi-Chang
AU  - Chen CC
AD  - IQVIA, Plymouth Meeting, PA, USA.
FAU - Nunna, Sasikiran
AU  - Nunna S
AD  - IQVIA, Plymouth Meeting, PA, USA.
FAU - Sun, Kainan
AU  - Sun K
AD  - IQVIA, Plymouth Meeting, PA, USA.
FAU - Kleinman, David M
AU  - Kleinman DM
AUID- ORCID: 0000-0002-1311-5216
AD  - Flaum Eye Institute, University of Rochester, Rochester, NY, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Med Econ
JT  - Journal of medical economics
JID - 9892255
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cohort Studies
MH  - Health Care Costs
MH  - Humans
MH  - Incidence
MH  - Medicare
MH  - *Multiple Myeloma/drug therapy
MH  - Retrospective Studies
MH  - United States/epidemiology
OTO - NOTNLM
OT  - I
OT  - I00
OT  - I1
OT  - I10
OT  - Multiple myeloma
OT  - corneal adverse events
OT  - economic burden
OT  - healthcare resource utilization
OT  - hematology
OT  - real-world
OT  - toxicity
EDAT- 2022/01/14 06:00
MHDA- 2022/02/08 06:00
CRDT- 2022/01/13 12:21
PHST- 2022/01/14 06:00 [pubmed]
PHST- 2022/02/08 06:00 [medline]
PHST- 2022/01/13 12:21 [entrez]
AID - 10.1080/13696998.2022.2029088 [doi]
PST - ppublish
SO  - J Med Econ. 2022 Jan-Dec;25(1):182-192. doi: 10.1080/13696998.2022.2029088.